CN1305468C - Bolengsu compound and its prepn, medicine composition and use - Google Patents
Bolengsu compound and its prepn, medicine composition and use Download PDFInfo
- Publication number
- CN1305468C CN1305468C CNB03123965XA CN03123965A CN1305468C CN 1305468 C CN1305468 C CN 1305468C CN B03123965X A CNB03123965X A CN B03123965XA CN 03123965 A CN03123965 A CN 03123965A CN 1305468 C CN1305468 C CN 1305468C
- Authority
- CN
- China
- Prior art keywords
- sex
- baill
- extract
- virus
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title abstract description 12
- 150000001875 compounds Chemical class 0.000 title description 43
- 241000530047 Herpetospermum pedunculosum Species 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 8
- 241000196324 Embryophyta Species 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 208000006454 Hepatitis Diseases 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 231100000283 hepatitis Toxicity 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 239000000969 carrier Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 241000700721 Hepatitis B virus Species 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims 2
- 206010061998 Hepatic lesion Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 241000709715 Hepatovirus Species 0.000 claims 1
- 230000003902 lesions Effects 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 11
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 230000002155 anti-virotic Effects 0.000 abstract description 2
- 230000000118 anti-eoplastic Effects 0.000 abstract 1
- 230000035492 administration Effects 0.000 description 21
- 229940079593 drugs Drugs 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 15
- 230000001629 suppression Effects 0.000 description 13
- 210000002966 Serum Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 9
- JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 8
- 229960001627 Lamivudine Drugs 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrugs Drugs 0.000 description 8
- -1 suspensoid Substances 0.000 description 8
- 241000272525 Anas platyrhynchos Species 0.000 description 7
- 125000006414 CCl Chemical group ClC* 0.000 description 7
- 101700052274 HBEAG Proteins 0.000 description 7
- 210000004185 Liver Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 241001597008 Nomeidae Species 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000001225 therapeutic Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000272522 Anas Species 0.000 description 5
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 5
- 208000002672 Hepatitis B Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000725618 Duck hepatitis B virus Species 0.000 description 4
- 206010019799 Hepatitis viral Diseases 0.000 description 4
- 230000000259 anti-tumor Effects 0.000 description 4
- 230000000840 anti-viral Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000002633 protecting Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 201000001862 viral hepatitis Diseases 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 241000530044 Herpetospermum Species 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 229940023488 Pill Drugs 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000024881 catalytic activity Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000005712 crystallization Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000003203 everyday Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N Butanol Natural products CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000002421 anti-septic Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000009030 carcinoma Diseases 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229960000829 kaolin Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- 229940008126 Aerosol Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic hepatitis Diseases 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101700075416 GPT Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 210000003141 Lower Extremity Anatomy 0.000 description 1
- 206010025482 Malaise Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000002200 Mouth Mucosa Anatomy 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 210000003928 Nasal Cavity Anatomy 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 210000004303 Peritoneum Anatomy 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 101710027046 SPBC582.08 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Stearin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000208 anti-hepatitis Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960000539 carbamide Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000003068 static Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
The present invention discloses an extraction of herpetospermumpeduncul-osum (Sex.) baill. And herpetin of cucurbitaceous plant, and also relates to a preparation method for the extraction of herpetospermumpeduncul-osum (Sex.) baill. And the herpetin, a medicine composition of the extraction of herpetospermumpeduncul-osum (Sex.) baill., the herpetin and a derivative of the herpetin, and a purpose of the herpetin, the derivative of the herpetin and the medicine composition as medicine, particularly a purpose for preparing antivirus medicine, hepatic injury resistant medicine and antineoplastic medicine. The present invention is verified by a cell experiment and an animal experiment, and herpetospermumpeduncul-osum (Sex.) baill. Has the advantages of high reactivity and little toxicity.
Description
Technical field
The present invention relates to cucurbitaceous plant ripple rib Herpetospermumpedunculosum (Sex.) Baill. extract and Bolengsu, the preparation method of ripple rib extract and Bolengsu, the pharmaceutical composition of ripple rib extract and Bolengsu and derivant thereof, ripple rib extract and Bolengsu and derivant thereof and pharmaceutical composition thereof are as the purposes of medicine, especially prepare antiviral, anti-liver injury, the purposes in the anti-tumor drug.Confirm that through cell experiment and zoopery Bolengsu has the advantage that activity is high, toxicity is little.
Background technology
Chronic viral hepatitis is the common transmittable disease of serious harm people ' s health.Only hepatitis B patient just accounts for 5% of world population according to statistics.Sickness rate height in China's viral hepatitis occupies first place in the world, and promptly about 80% hepatitis concentrates on China.The existing Patients with Viral Hepatitis of China reaches more than 3,000 ten thousand people at present, has every year nearly 500,000 people to die from and the hepatitis B diseases associated.Therefore, chronic viral hepatitis particularly the treatment of hepatitis B be the difficult problem of world the world of medicine always.
Because huge hepatitis B crowd demands urgently obtaining medical treatment, therefore, the medicine of chronic hepatitis is various in style on the China market at present, according to incompletely statistics, and kind surplus Chinese and western drugs has reached 700, but the medicine that curative effect is sure, side effect is little is few in number.Although the popularization of hepatitis vaccine prevents and treats hepatitis and plays huge impetus, hepatitis still increases with the speed in every year nearly 1,000,000.Therefore, the development novel structure, it is still very urgent to act on sure novel antihepatitis drug.Lamivudine is the medicine of the hepatitis virus resisting of generally acknowledging in the existing medicine, but lamivudine costs an arm and a leg, and requires the patient to take medicine for a long time, and be indefinite the course of treatment, and knock-on is strong and bigger Liver and kidney toxicity arranged after patient's drug withdrawal.Also do not have to kill hepatitis virus now and can protect hepatocellular medicine again.
Cucurbitaceous plant Herpetospermum pedunculosum (Sex.) Baill. ripple rib is a kind of plant that is grown in Tibet, does not see the medicinal report to it.
Summary of the invention
In order to overcome the weak point of prior art, the object of the present invention is to provide the antiviral of cucurbitaceous plant Herpetospermum pedunculosum (Sex.) Baill. ripple rib, anti-chemical damage, anti-tumor application.
Another object of the present invention is to provide the extract of cucurbitaceous plant Herpetospermumpedunculosum (Sex.) Baill. ripple rib.
Another purpose of the present invention is to provide cucurbitaceous plant Herpetospermumpedunculosum (Sex.) Baill. ripple rib preparation method of extract.
Another order of the present invention is to provide the pharmaceutical composition that contains ripple rib extract, and it comprises as carrier commonly used in the extract of cucurbitaceous plant Herpetospermum pedunculosum (Sex.) the Baill. ripple rib of active ingredient and the pharmaceutical field.
The antiviral that another purpose of the present invention is cucurbitaceous plant Herpetospemumpedunculosum (Sex.) Baill. ripple rib extract is provided and contains its pharmaceutical composition, anti-chemical damage, anti-tumor application.
Another purpose of the present invention is to provide a kind of new Bolengsu chemical compound.
Another purpose of the present invention is to provide a kind of preparation method of new Bolengsu.
Another purpose of the present invention is to provide the Bolengsu pharmaceutical composition, and it comprises as carrier commonly used in the Bolengsu chemical compound of active ingredient and isomer and the pharmaceutical field.
Another purpose of the present invention is to provide Bolengsu derivant and compositions thereof as antiviral, anti-chemical damage, the application of antitumor drug.
One aspect of the present invention relates to the Bolengsu shown in general formula (I), and relevant enantiomer, diastereomer, polymorph, ester, salt and solvation form:
The present invention also comprises the derivant of general formula compound I, their stereoisomer, their polymorph, their pharmaceutically acceptable salt, their pharmaceutically acceptable solvate.
The present invention relates to shown in general formula I acceptable derivates or prodrug on the chemical compound drug effect, the meaning is any acceptable salt of chemical compound shown in general formula I, the salt of ester and ester; Perhaps other derivant of The compounds of this invention, its when giving the receptor, can be direct or indirect chemical compound of the present invention is provided.Especially preferred derivant and prodrug are, when this chemical compound gives mammal, can increase The compounds of this invention stability, and/or can increase the The compounds of this invention bioavailability (for example, make the chemical compound of oral administration be easier to be absorbed into blood), and/or can increase this chemical compound in the distribution that is relevant to the biological compartment of these species (for example, liver, tumor).Prodrug is passing through linking to each other of covalent bond of any and carrier, and when this prodrug gave mammalian subject, it discharged in vivo as active this chemical compound of general formula I.Preferred prodrug comprises, but is not limited to, and increases water solublity or the group by biomembranous active permeability and connects the derivant that the structure as general formula I forms.The preparation of the prodrug of compound of Formula I is the substituent group that exists in the chemical compound by being modified at, and with such method, this modification is can be isolating for this chemical compound, no matter is with in the conventional method or body.Prodrug comprises that hydroxyl connects any substituent group in the chemical compound of general formula I, when giving mammalian subject, forms hydroxyl freely after the separation.The embodiment of prodrug comprises, but is not limited to, the acetylation of hydroxyl in the compound of Formula I, and formylated, etc.
The various polymorphs of the chemical compound shown in general formula I constitute part of the present invention and can prepare by the compound crystal under different conditions.For example, use different normally used solvents or their mixture to come crystallization; Crystallization under different temperature; Various pattern is cooled off; In crystallization process, from very near very slow scope.Polymorph can be followed progressive or cooling fast obtains by heating or melting compound.The existence of polymorph can NMR, IR, and the scanning of heat difference, X-light powder diffraction or other technology are proved conclusively.
Chemical compound of the present invention can be modified by connecting similar functional group increases the biological property of selection.This being modified at is known in the art, including but not limited to, those increases penetrate into specific biological compartment (for example liver), increase oral or intravenous bioavailability, increase dissolubility and allow to change metabolism by drug administration by injection, change excretory speed, or the like.
In order to finish the object of the invention, the present invention takes following technical scheme:
The extract of cucurbitaceous plant ripple rib Herpetospermum pedunculosum (Sex.) Baill. and the preparation of Bolengsu
Root, stem, leaf, the seed of crude drug cucurbitaceous plant ripple rib Herpetospermumpedunculosum (Sex.) Baill., its seed Herpetospermum caudigerum Wall. preferably, drying and suitable pulverizing in order to the contact area that increases with solvent, are raised the efficiency.
The extraction solvent of crude drug can make the mixture of water, alcohols or water and alcohols.Preferred alcohols, especially low-molecular-weight alcohol comprises methanol, ethanol, isopropyl alcohol, butanols etc., more preferably ethanol.During extraction quantity of solvent be former medicine weight 2-20 doubly.Can soak before extracting.Extraction can be static or down dynamic, preferably under dynamic condition.In order to improve the efficient of extraction, can use ultrasound wave etc.The temperature of extracting be from room temperature (for example 20 ℃) to the scope of solvent refluxing temperature in, preferably under the temperature of backflow.Extraction can be carried out continuously or intermittently, can repeat 1-4 time during intermittent extraction.
Behind the last EOS, merging filtrate, elimination medicinal residues.Filtrate is concentrated into the extractum that does not have solvent at normal pressure or decompression heating under dynamical state.
After the removing oil of extractum petroleum ether, ethyl acetate extraction.Reclaim ethyl acetate, get dry powder.
Dry powder carries out purification, carries out column chromatography, can pass through macroporous resin, ion exchange resin, adsorpting column chromatography, preferred adsorpting column chromatography, and more preferably silica gel column chromatography is the effective site that chromatography obtains.Elution system can be sieved with thin layer chromatography, selects to make the solvent system of the Rf value of separated component at 0.2-0.3.Preferably use dichloromethane: 50: 1,30: 1,10: 1,5: 1,1: 1 gradient elution of acetone, collect eluate in 10: 1,5: 1,1: 1, get the Bolengsu crude product.
The Bolengsu crude product is again through HPLC preparation, chemical compound that can be shown in general formula I, and purity is more than 98%.
The present invention also provides the pharmaceutical composition of extract of the present invention, chemical compound, and it comprises medicine effective dose, as extraction of active ingredients thing, chemical compound and pharmaceutically acceptable carrier.
Usually pharmaceutical composition of the present invention contains extract of the present invention, the chemical compound of 0.1-95% weight.
The pharmaceutical composition of extract of the present invention, chemical compound can be according to method preparation well known in the art.When being used for this purpose, if desired, extract of the present invention, chemical compound and one or more solids or liquid medicine excipient and/or adjuvant can be combined, make and can be used as suitable administration form or the dosage form that people's medicine or veterinary drug use.
Extract of the present invention, chemical compound or contain its pharmaceutical composition can the unit dosage form administration, route of administration can be intestinal or non-intestinal, as oral, muscle, subcutaneous, nasal cavity, oral mucosa, skin, peritoneum or rectum etc., preferred oral administration.
Extract of the present invention, chemical compound or the route of administration that contains its pharmaceutical composition can be drug administration by injection.Injection comprises intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection etc.
Form of administration can be liquid dosage form, solid dosage forms.As liquid dosage form can be true solution class, colloidal type, particulate formulations, emulsion dosage form, mixed suspension form.Other dosage forms are tablet, capsule, drop pill, aerosol, pill, powder, solution, suspensoid, Emulsion, granule, suppository, lyophilized injectable powder etc. for example.
Extract of the present invention, chemical compound can be made ordinary preparation, also can be slow releasing preparation, controlled release preparation, targeting preparation and various particulate delivery system.
For the unit form of administration is made tablet, can be extensive use of various carrier well known in the art.Example about carrier is, for example diluent and absorbent are as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, carbamide, calcium carbonate, kaolin, microcrystalline Cellulose, aluminium silicate etc.; Wetting agent and binding agent are as water, glycerol, Polyethylene Glycol, ethanol, propanol, starch slurry, dextrin, syrup, Mel, glucose solution, mucialga of arabic gummy, gelatine size, sodium carboxymethyl cellulose, lac, methylcellulose, potassium phosphate, polyvinylpyrrolidone etc.; Disintegrating agent, for example dry starch, alginate, agar powder, laminaran, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene sorbitol fatty acid ester, dodecyl sodium sulfate, methylcellulose, ethyl cellulose etc.; Disintegrate inhibitor, for example sucrose, glyceryl tristearate, cocoa butter, hydrogenation wet goods; Absorption enhancer, for example quaternary ammonium salt, sodium lauryl sulphate etc.; Lubricant, for example Pulvis Talci, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, Polyethylene Glycol etc.Tablet further can also be made coated tablet, for example sugar coated tablet, thin membrane coated tablet, ECT, or double-layer tablet and multilayer tablet.
For example, can be extensive use of various carrier well known in the art for pill is made in the administration unit.Example about carrier is, for example diluent and absorbent are as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, Kaolin, Pulvis Talci etc.; Binding agent is as arabic gum, Tragacanth, gelatin, ethanol, Mel, liquid sugar, rice paste or batter etc.; Disintegrating agent is as agar powder, dry starch, alginate, dodecyl sodium sulfate, methylcellulose, ethyl cellulose etc.
For example for capsule is made in the administration unit, effective ingredient extract of the present invention, chemical compound are mixed with above-mentioned various carriers, and the mixture that will obtain thus places hard gelatine capsule or soft capsule.Also effective ingredient extract of the present invention, chemical compound can be made microcapsule, be suspended in and form suspensoid in the aqueous medium, in the hard capsule of also can packing into or make injection and use.
For example, extract of the present invention, chemical compound are made injection preparation, as solution, suspensoid solution, Emulsion, lyophilized injectable powder, this preparation can be moisture or non-water, can contain acceptable carrier, diluent, binding agent, lubricant, antiseptic, surfactant or dispersant on a kind of and/or multiple pharmacodynamics.Can be selected from water, ethanol, Polyethylene Glycol, 1 as diluent, the isooctadecanol of ammediol, ethoxylation, the isooctadecanol of polyoxyization, Polyoxyethylene Sorbitol Fatty Acid Esters etc.In addition, ooze injection, can in injection preparation, add proper amount of sodium chloride, glucose or glycerol, in addition, can also add conventional cosolvent, buffer agent, pH regulator agent etc. in order to prepare etc.These adjuvants are that this area is commonly used
In addition, as needs, also can in pharmaceutical preparation, add coloring agent, antiseptic, spice, correctives, sweeting agent or other material.
For reaching the medication purpose, strengthen therapeutic effect, medicine of the present invention or pharmaceutical composition can be with any known medication administrations.
The dosage of extract of the present invention, compound medicine compositions depends on many factors, for example to prevent or treat the character and the order of severity of disease, the sex of patient or animal, age, body weight, personality and individual reaction, route of administration, administration number of times, therapeutic purposes, therefore therapeutic dose of the present invention can have large-scale variation.In general, the using dosage of Chinese materia medica composition of the present invention is well known to a person skilled in the art.The actual drug quantity that can be according to the present invention be contained in the last preparation in extract, the compound composition, in addition suitable adjustment to reach the requirement of its treatment effective dose, is finished prevention of the present invention or therapeutic purposes.The consumption of the suitable dose scope extract of the present invention of the every day of extract of the present invention, chemical compound is the 0.001-100mg/Kg body weight, is preferably the 0.01-60mg/Kg body weight, and more preferably the 0.05-10mg/Kg body weight most preferably is the 0.1-1mg/Kg body weight.Above-mentioned dosage can the single dose form or be divided into several, for example two, three or four dosage form administrations this be subject to administration doctor's clinical experience and comprise the dosage regimen of using other treatment means.Each treats that required accumulated dose can be divided into repeatedly or by the dose administration.Extract of the present invention or compositions can be taken separately, or merge use and adjust dosage with other treatment medicine or symptomatic drugs.
Bolengsu of the present invention has good antivirus action, especially hepatitis virus resisting effect.Give Bolengsu after experiment shows duckling infected duck hepatitis B virus (DHBV), one day 2 times 10 days inhibition effects to the hepatitis b virus infected clear middle DHBVDNA level of Sanguis Anas domestica of infected duck of Bolengsu 0.08g/kg have significance effect, non-toxic reaction; 0.16g/kg the group inhibitory action is also stronger.Compare with the positive drug lamivudine, 0.08g/kg group inhibitory action in the time of 10 days is stronger, and knock-on is slow.Above experimental result shows: Bolengsu has stronger inhibitory action to hepatitis B virus.
Pharmacological evaluation shows: Bolengsu adds in the 2.2.15 cell culture fluid can obviously suppress duplicating and expressing of HBsAg and HBeAg, illustrates that chemical compound of the present invention has inhibitory action to hepatitis B virus.
Bolengsu of the present invention has stronger function for protecting liver and reducing enzyme activity.To disposable ip carbon tetrachloride (CCl
4) in the induced mice acute liver damage experiment, each administration group rat blood serum GPT, GOT value all are lower than model control group, Bolengsu height, middle dosage group and model group relatively have significant difference, illustrate that Bolengsu is to CCl
4The induced mice acute liver damage has therapeutical effect preferably.To disposable ip carbon tetrachloride (CCl
4) rising of induced mice serum glutamic pyruvic transminase (GPT), glutamic oxaloacetic transaminase, GOT (GOT) also has stronger inhibitory action.Illustrate that Bolengsu of the present invention has stronger function for protecting liver and reducing enzyme activity, especially to chemical substance, CCl particularly
4The hepatic injury that causes, Bolengsu have good protective effect.
Bolengsu of the present invention has stronger antitumor action.Respectively with human hepatoma cell strain BEL-7402, BEL-7404, and human colon cancer cell strain HCT be object of study, with culture medium and the cell co-cultivation that contains different diluted concentration Bolengsus, the effect of employing mtt assay detection of drugs is to the inhibitory action of cancerous cell.The result shows: Bolengsu is respectively 1.44,1.64 to 50% suppression ratio of BEL-7402, BEL-7404, is 2.31 to 50% suppression ratio of HCT.Illustrate that The compounds of this invention has the obvious suppression effect to the different carcinoma cell in-vitro growth.
Description of drawings
The preparation technology figure of cucurbitaceous plant Herpetospermum pedunculosum (Sex.) Baill. ripple rib extract (is crude drug with the Herpetospermum caudigerum Wall.) and Bolengsu.
The specific embodiment
The experiment of the following examples and pharmaceutically active is used for further specifying the present invention, but this and do not mean that any limitation of the invention.
The preparation of embodiment 1 cucurbitaceous plant Herpetospermum pedunculosum (Sex.) Baill. ripple rib extract and Bolengsu
The seed Herpetospermum caudigerum Wall. 5kg of material ripple rib gets it filled, pulverize, soak with 95% ethanol (5 times of amounts), alcohol reflux 3 times, each 1h, merge extractive liquid,, be concentrated into and do not have the alcohol flavor, leave standstill and remove oil reservoir, after petroleum ether (one times of amount) is sloughed residual oil, ethyl acetate (one times of amount, one times of amount, one times of amount) extraction three times.Reclaim ethyl acetate, get dry powder.This part is used dichloromethane successively through silica gel column chromatography repeatedly: 50: 1,30: 1,10: 1,5: 1,1: 1 gradient elution of acetone, collect eluate in 10: 1,5: 1,1: 1, the Bolengsu crude product.
It is more than 98% that the Bolengsu crude product is prepared into Bolengsu (HPLC condition) purity through HPLC.Idiographic flow is seen accompanying drawing.
C
13-NMR、C
13-H
1cosy：
| C number | Chemical shift (δ ppm) | The H number |
| 1 | 146.79 | C |
| 2 | 113.39 | CH |
| 3 | 134.51 | C |
| 4 | 117.30 | CH |
| 5 | 146.06 | C |
| 6 | 55.79 | CH 3 |
| 7 | 129.16 | C |
| 8 | 54.36 | CH |
| 9 | 63.90 | CH 2 |
| 10 | 88.05 | CH |
| 11 | 133.69 | C |
| 12 | 118.83 | CH |
| 13 | 115.14 | CH |
| 14 | 146.53 | C |
| 15 | 148.02 | C |
| 16 | 53.38 | CH 3 |
| 17 | 109.69 | CH |
| 18 | 32.97 | CH 2 |
| 19 | 42.96 | CH |
| 20 | 72.53 | CH 2 |
| 21 | 83.07 | CH |
| 22 | 53.07 | CH |
| 23 | 59.48 | CH 2 |
| 24 | 134.74 | C |
| 25 | 118.83 | CH |
| 26 | 115.01 | CH |
| 27 | 148.09 | C |
| 28 | 55.41 | CH 3 |
| 29 | 144.37 | C |
| 30 | 109.59 | CH |
Pharmacological evaluation
Hepatitis virus resisting effect in the body of experimental example 1 Bolengsu
1.1 the reagent lamivudine, Britain Glaxo Wellcome company limited B022306.A-
32P-dCTP (the auspicious biotechnology of Beijing good fortune engineering company, lot number: 981206); Nick translation medicine box (Promega company, lot number: 990426); DHB is DHB DNA (DHBV-DNA) strong positive Shanghai sheldrake serum (medical biotechnology institute of Chinese Academy of Medical Sciences Viral Laboratory provides ,-70 ℃ of preservations)
1.2 animal 1 age in days Beijing dimension duck is available from Nangyuan District, Beijing duckery
1.3 method 1 age in days Beijing duck, clear through the positive Sanguis Anas domestica of lower limb shin intravenous injection Shanghai sheldrake DHBV-DNA, every 0.3ml infects and got blood in back 7 days, and separation of serum detects DHBVDNA content in the serum.Duckling serum is divided into 5 groups at random with duck after DHBV is positive after testing, three dosage groups of virus control group, lamivudine group (50mg/kg), Bolengsu (160,80,40mg/kg), 6 every group.Gastric infusion, 1.5ml/, every day 2 times.Matched group gives with the volume normal saline, successive administration 10 days.Respectively at 5 days (T after the Drug therapy
5), 10 days (T
10) and drug withdrawal after 3 days (P
3) get blood from duck shin vein, separation of serum is pressed nick translation test kit description method, uses
32P labelling DHBVDNA probe, and make the clear dot blot hybridization of Sanguis Anas domestica, autoradiography diaphragm speckle, microplate reader is measured OD value (optical filter is 490nm), calculating serum DHBV-DNA optical density, with hybridization spot OD value as specimen DHBV-DNA level value.
Shine the horizontal rejection ratio of the group clear DHBV-DNA of Sanguis Anas domestica when table 1 Bolengsu treatment group and viral infection
| Medicine | Dosage g/kg | Number of animals (only) | Suppression ratio (%) | ||
| T 5 | T 10 | P 3 | |||
| Virus control group Bolengsu | 0.04 0.08 | 6 6 6 | -0.81 18.24* 24.99* | 15.65 34.88* 62.48** | -8.56 23.06 45.85** |
| Lamivudine | 0.16 0.05 | 6 6 | 21.66* 45.27** | 58.45** 56.92** | 37.68** 27.35* |
Statistical disposition: drug treatment group HBV-DNA suppression ratio and virus control group compare (t check in groups) with the DHBV-DNA suppression ratio of time.
*P＜0.05，
**P＜0.01，
***P＜0.001。
Experimental result shows that one day 2 times 10 days inhibition effects to the hepatitis b virus infected clear middle DHBVDNA level of Sanguis Anas domestica of infected duck of Bolengsu 0.08g/kg have significance effect, non-toxic reaction; 0.16g/kg the group inhibitory action is also stronger, with 0.08g/kg group there was no significant difference.Compare with the oral inhibitory action to DHBVDNA of positive drug lamivudine, 0.08g/kg group inhibitory action in the time of 10 days is stronger, and knock-on is slow, but does not have significant difference on the statistics.Above experimental result shows: Bolengsu has good therapeutical effect to the duck hepatitis B virus infection duck, and is better than the positive drug lamivudine.
The hepatitis virus resisting effect of experimental example 2 Bolengsus
2.1 reagent
DMEM (U.S. Gibco company product); Hyclone (U.S. Gibco company product); G-418 (U.S. Sigma company product); HBeAg, HBsAg immobile phase radioimmunoassay box (Beifang Inst. of Immune Reagents, Chinese Isotopes Co.'s product);
2.2.2.2.15 cell the has been transfection full genome of HBV (Aayw subunit), can secrete HBsAg, HBeAg, the female oncocyte of the particulate people liver of HBV-DNA system, U.S. Mount sinai medical center makes up, the cultivation of going down to posterity of medical biotechnology institute of Chinese Academy of Medical Sciences Viral Laboratory)
2.3 method is with 100,000 every milliliter 2.2.15 cell inoculation 24 well culture plates, every hole 1ml, 37 ℃ of 5%CO
2Cultivated 24 hours, and added the following 2 times of dilution test medicinal liquids of non-toxic concn, 5 dilution factors are respectively 4,2,1,0.5,0.25mg/ml, every concentration 3 holes, 37 ℃ of 5%CO
2Cultivate, collect the 8th day pastille culture fluid ,-20 ℃ of stored frozen.Measure with reference to solid phase radioimmunoassay box description, measure every hole cpm value with the γ calculating instrument.HBsAg, the HBeAg positive and negative control are established in experiment.
Table 2 Bolengsu in the 2.2.15 cell to the influence of HBsAg
| Drug level mg/ml | cpm(x±s) | Suppression ratio % |
| 0.006 0.003 0.0015 cell contrast | 2158±176 1774±63 3206±216 7069±245 | 63.02 ** 69.60 ** 44.15 * |
Compare * * p＜0.01 * p＜0.05 with cell
Table 3 Bolengsu in the 2.2.15 cell to the influence of HBeAg
| Drug level mg/ml | cpm(x±s) | Suppression ratio % |
| 0.006 0.003 0.0015 cell contrast | 1073±213 1224±120 1507±185 2753±123 | 61.04 55.53 45.26 |
Compare * * p＜0.01 * p＜0.05 with cell
Experiment shows: Bolengsu added the 2.2.15 cell culture 8 days, obviously suppressed the secretion of HBsAg and HBeAg, can suppress duplicating and expressing of 2.2.15 cell HBsAg, HBeAg.The compounds of this invention illustrates that in the 2.2.15 cell culture hepatitis B virus being had inhibitory action it has stronger inhibitory action to hepatitis B virus.
The function for protecting liver and reducing enzyme activity of experimental example 3 Bolengsus
3.1 positive control drug: 99J15043L01 bifendate, Beijing XieHe medicine Factory, lot number: 010309;
3.2 reagent: glutamate pyruvate transaminase (GPT), glutamic oxaloacetic transaminase, GOT (GOT) are measured test kit, be the safe clinical reagent company limited of Beijing northization product E agles MEM dry powder, G-418 (Geneticin), yeast t-RNA, E.C. 3.4.21.64, U.S. GIBCO company product;
3.3 animal: Kunming mouse, body weight 18-22g, all male and female half and half are provided by Military Medical Science Institute's animal center, and the animal quality certification number is respectively the moving word BDW98012 of medical officer and the moving word of medical officer BDW95001 number.The zoopery condition: two grade standards, the quality certification number: medical officer moves word B98006.
3.4 instrument BS-224 type biochemical analysis analyzer, Beijing biochemical instrument factory.
3.5 getting 60 of healthy mices, method is divided into six groups at random, i.e. normal control group, CCl
4(0.02ml/kg) three dosage groups of model group, bifendate group 0.029g/kg, Bolengsu (0.0166,0.0083,0.0042g/kg), 10 every group.Every day, the ig administration was 2 times, and matched group and model group are given the distilled water with same volume, behind 7 medicines of successive administration, and except that the normal control group, ip in mice 0.1%CCl
4(olive oil is a solvent) 0.02ml/g, after the modeling 40 hours, mice socket of the eye venous blood collection was surveyed serum GPT, GOT value, sees Table 4.
Table 4. Bolengsu causes the influence of chmice acute hepatic injury to CCl4
| Group | Dosage (g/kg) | Number of animals (only) | GPT (U·L -1) | GOT (U·L -1) |
| Matched group model group bifendate Bolengsu | 0.029 0.0166 0.0083 0.0042 | 10 10 10 10 10 10 | 10.90±0.85 152.31±20.34 ## 30.71±2.28 ** 34.20±10.12 ** 36.22±10.03 ** 62.75±8.21 * | 49.59±5.731 162.92±9.08 ## 70.14±8.06 * 72.43±9.11 * 69.12±8.97 * 86.28±10.23 * |
Compare with the normal control group, * p＜0.05 * * p＜0.01 is compared with model group in #p＜0.05 ##p＜0.01
The result shows that each administration group rat blood serum GPT, GOT value all are lower than model control group, and Bolengsu height, middle dosage group and model group relatively have significant difference, illustrate that Bolengsu is to CCl
4The induced mice acute liver damage has therapeutical effect preferably.
Experimental example 4 antitumor actions
4.1 method respectively with human hepatoma cell strain BEL-7402, BEL-7404, and human colon cancer cell strain HCT be object of study, with culture medium and the cell co-cultivation that contains different diluted concentration Bolengsus, adopt the inhibitory action of mtt assay detection of drugs effect to cancerous cell.Revise [1] slightly according to literature method, target cell is adjusted to 1 * 10 with complete culture solution
5/ mL is inoculated in respectively in 96 well culture plates, and every hole 100 μ L add different pastille serum of 100 μ L and blank serum then respectively, and cumulative volume 200 μ L establish 7 parallel holes for every group, at 37 ℃, 5%CO
2, cultivate 48h under the saturated humidity condition after, every hole adds 5mL MTT 10 μ L, carries out chromogenic reaction after continuing to cultivate 4h, add 20% dimethyl sulfoxide, 100 μ L cessation reactions, concussion 10min, at DG3022-A type enzyme-linked immunosorbent assay instrument, wavelength 570nm surveys absorbance (A) value.The cytotoxic activity computing formula is:
Result: see Table 5.
Table 5. Bolengsu is to the suppression ratio (%) of growth of tumour cell
| Cell strain | Concentration (μ g/ml) | |||||
| 1.25 | 2.50 | 5.00 | 10.00 | 20.00 | IC50 | |
| BEL-7402 BEL-7404 HCT | 34.90 12.30 32.00 | 41.90 60.00 18.00 | 100.00 100.00 72.00 | 98.80 98.50 100.00 | 100.00 100.00 100.00 | 1.44 1.64 2.31 |
The result shows: Bolengsu is respectively 1.44,1.64 to 50% suppression ratio of BEL-7402, BEL-7404, is 2.31 to 50% suppression ratio of HCT.Illustrate that chemical compound of the present invention has the obvious suppression effect to the different carcinoma cell in-vitro growth.
Claims (12)
1, the application of cucurbitaceous plant ripple rib Herpetospermum pedunculosum (Sex.) Baill. in the anti-hepatic lesions medicine of preparation, wherein said hepatic lesions is meant hepatovirus, hepatic injury and liver tumor.
According to the application of claim 1, it is characterized in that 2, described virus is hepatitis virus.
According to the application of claim 2, it is characterized in that 3, described hepatitis virus is a hepatitis B virus.
According to the application of claim 1, it is characterized in that 4, described hepatic injury is chemical hepatic injury.
5, the extract of cucurbitaceous plant Herpetospermum pedunculosum (Sex.) Baill. ripple rib, it is characterized in that, described extract prepares by following method: with the solvent extraction of cucurbitaceous plant Herpetospermumpedunculosum (Sex.) Baill. ripple rib, merge extractive liquid,, concentrate, the petroleum ether removing oil, ethyl acetate extraction, concentrate dry powder, dry powder is through silica gel column chromatography repeatedly, use dichloromethane successively: acetone 50: 1,30: 1,10: 1,5: 1,1: 1 gradient elution was collected 10: 1,5: 1,1: 1 eluate gained.
6, cucurbitaceous plant Herpetospermum pedunculosum (Sex.) Baill. ripple rib preparation method of extract, it is characterized in that, the solvent extraction of cucurbitaceous plant Herpetospermum pedunculosum (Sex.) Baill. ripple rib, merge extractive liquid,, concentrate, the petroleum ether removing oil, ethyl acetate extraction, concentrate dry powder, dry powder is through silica gel column chromatography repeatedly, use dichloromethane successively: 50: 1,30: 1,10: 1,5: 1,1: 1 gradient elution of acetone, collect eluate in 10: 1,5: 1,1: 1.
According to the preparation method of claim 6, it is characterized in that 7, described solvent is an ethanol.
8, the pharmaceutical composition of a kind of cucurbitaceous plant Herpetospermum pedunculosum (Sex.) Baill. ripple rib extract, it is characterized in that, comprise as carrier commonly used in the extract of the described cucurbitaceous plant Herpetospermumpedunculosum of the claim 5 of active ingredient (Sex.) Baill. ripple rib and the pharmaceutical field.
9, cucurbitaceous plant Herpetospermumpedunculosum as claimed in claim 5 (Sex.) Baill. ripple rib extract is in the anti-hepatovirus of preparation, anti-chemical damage, the application in the anti-liver tumor medicine.
According to the application of claim 1, it is characterized in that 10, described virus is hepatitis virus.
According to the application of claim 2, it is characterized in that 11, described hepatitis virus is a hepatitis B virus.
According to the application of claim 1, it is characterized in that 12, described hepatic injury is chemical hepatic injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03123965XA CN1305468C (en) | 2003-05-29 | 2003-05-29 | Bolengsu compound and its prepn, medicine composition and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03123965XA CN1305468C (en) | 2003-05-29 | 2003-05-29 | Bolengsu compound and its prepn, medicine composition and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1486691A CN1486691A (en) | 2004-04-07 |
| CN1305468C true CN1305468C (en) | 2007-03-21 |
Family
ID=34152849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB03123965XA Expired - Fee Related CN1305468C (en) | 2003-05-29 | 2003-05-29 | Bolengsu compound and its prepn, medicine composition and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1305468C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013064128A1 (en) | 2011-10-31 | 2013-05-10 | 浙江贝达药业有限公司 | Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100333736C (en) * | 2004-07-26 | 2007-08-29 | 杨东平 | Medication for treating ascites of liver, cirrhosis of liver and liver cancer in early stage |
| CN100389785C (en) * | 2006-04-04 | 2008-05-28 | 钱毓洲 | Pedunculate herpetospermum seed extract, its dripping pill and their preparing method and application |
| CN101311173B (en) * | 2007-05-25 | 2010-07-28 | 成都中医药大学 | Herpe-lactone, preparation method and use thereof |
| CN102000136B (en) * | 2010-11-25 | 2012-04-18 | 西南大学 | Method for extracting components having antibacterial activity from fruit of pedunculate herpetospermum |
| CN102140101B (en) * | 2011-03-24 | 2013-04-10 | 中国人民解放军第三〇二医院 | Method for preparing Herperione, application thereof, capsule thereof, preparation method and application of capsule |
| CN105311637B (en) * | 2014-08-04 | 2019-07-09 | 西南民族大学 | A kind of pharmaceutical composition containing Bolengsu |
| WO2019213807A1 (en) * | 2018-05-07 | 2019-11-14 | 袁海龙 | Lignan active ingredient composition of herpetospermum caudigerum wall and preparation method therefor and application and dosage form thereof |
| CN111208224B (en) * | 2020-01-14 | 2022-10-21 | 南京理工大学 | Liquid chromatography detection method of herpetospermum pedunculosum seed shell extract |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1099883C (en) * | 2000-08-14 | 2003-01-29 | 久美彭措 | Tibeten medicine for treating hepatitis B and its preparation |
-
2003
- 2003-05-29 CN CNB03123965XA patent/CN1305468C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1099883C (en) * | 2000-08-14 | 2003-01-29 | 久美彭措 | Tibeten medicine for treating hepatitis B and its preparation |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013064128A1 (en) | 2011-10-31 | 2013-05-10 | 浙江贝达药业有限公司 | Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1486691A (en) | 2004-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100486595C (en) | Brazil mushroom soluble small molecular extract, its preparation technology and use | |
| CN1305468C (en) | Bolengsu compound and its prepn, medicine composition and use | |
| CN1660850A (en) | Method for preparing dehydrogenated cavidine, dehydrogenated apocavidine and combination | |
| CN101259124A (en) | Pharmaceutical use of wedelolactone and its derivative | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN107488162A (en) | A kind of bicyclic alcohol derivatives and its preparation and application | |
| CN101058594A (en) | Sarcandra glabra effective constituent, preparation method thereof, medicament composition and use of the same | |
| CN1895220A (en) | 20(R)-ginseng sapoglycoside Rg3 medicinal soluble intermediate and its production | |
| CN1182851C (en) | Separating prepn process of effective part and active component of influenze virus resisting medicine | |
| CN1118471C (en) | Medicine containing tan matter caesalpinia extract | |
| CN1296089C (en) | Zedoary injection preparation and its preparing method | |
| US20020077351A1 (en) | TNF-alpha production inhibitor comprising kavalactone as an active ingredient | |
| CN111202737B (en) | Application of tripterine amide derivative in preparation of medicine for treating autoimmune diseases | |
| CN101774920A (en) | Preparation method of 3,5-cynarin methyl ester and medicament composition thereof | |
| CN1775217A (en) | Medicinal composition for treating Heptitis B | |
| US11248002B2 (en) | Sesquiterpene derivative and use of the same in preparation of medicament for treating hepatitis b diseases | |
| CN1660836A (en) | Compound of dehydrogenated cavidine group and application in medication | |
| CN1895257A (en) | Use of 20(S)-protopanoxadiol in preparation of anti-bowelcancer medicine | |
| CN101774921A (en) | Method for preparing dicaffeoylquinic acid methyl compound and composition thereof | |
| CN101735189A (en) | Preparation method, preparation and application of tricin | |
| CN1295231C (en) | Bromo-dihydroartemisine | |
| CN1695630A (en) | Application of peripocin in preparing medication for preventing and treating tumour | |
| CN1289505C (en) | New compound,its preparation method, medicine preparation using said compound as active component, its action and application | |
| CN102451220A (en) | Erythrophleum fordii Oliver extract, preparation method and pharmaceutical composition thereof and application | |
| CN102584846A (en) | Curcumenol derivatives resisting influenza A(H1N1) virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| C49 | Reinstatement of patent right or utility model | ||
| RR01 | Reinstatement of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070321 Termination date: 20200529 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |